#1 Clinical Trials Search in Europe

Dalbavancin

Dalbavancin is an innovative antibiotic being studied in clinical trials for treating various bacterial infections. This long-acting medication shows potential for reducing hospital stays and improving patient outcomes across different types of infections. The following article summarizes key findings from recent clinical trials investigating dalbavancin’s effectiveness and safety.

Table of Contents

What is Dalbavancin?

Dalbavancin is a powerful antibiotic used to treat certain types of bacterial infections. It belongs to a class of drugs called lipoglycopeptides, which are designed to fight against gram-positive bacteria. These are a specific type of bacteria that can cause serious infections[1]. Dalbavancin is also known by its brand names Xydalba® and Dalvance®[2][3].

How Does Dalbavancin Work?

Dalbavancin works by attacking the cell walls of gram-positive bacteria, which ultimately leads to their death. What makes dalbavancin unique is its long-lasting effect in the body. Unlike many other antibiotics that require daily doses, dalbavancin can remain active in the body for an extended period, allowing for less frequent dosing[3].

What Conditions Does Dalbavancin Treat?

Dalbavancin is primarily used to treat the following conditions:

  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): These are serious skin infections that can involve deeper layers of skin and surrounding tissues[2].
  • Gram-positive bacteremia: This is a condition where bacteria are present in the bloodstream[4].
  • Osteoarticular infections: These are infections affecting bones and joints, particularly those associated with hip and knee replacements[5].
  • Peritonitis: An infection of the abdominal lining, particularly in patients undergoing peritoneal dialysis[6].

How is Dalbavancin Administered?

Dalbavancin is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosing schedule can vary depending on the specific condition being treated, but generally, it involves one or two doses given over a period of 1-2 weeks[2]. For example:

  • A single dose of 1500 mg
  • Two doses: 1000 mg on day 1, followed by 500 mg on day 8

This unique dosing schedule is one of the key advantages of dalbavancin[3].

Benefits of Dalbavancin

Dalbavancin offers several benefits over traditional antibiotics:

  1. Convenience: Its long-acting nature means fewer doses are needed, which can reduce hospital stays and allow for outpatient treatment[3].
  2. Improved compliance: With fewer doses, patients are more likely to complete their full course of treatment[4].
  3. Reduced risk of infection: Less frequent IV access can lower the risk of catheter-related infections[4].
  4. Cost-effective: By potentially reducing hospital stays, dalbavancin may lead to overall cost savings in healthcare[3].

Ongoing Research and Future Applications

Researchers are continually exploring new uses for dalbavancin. Some areas of ongoing research include:

  • Treatment of infections in people who use drugs (PWUD), where maintaining IV access for traditional antibiotics can be challenging[4].
  • Use in pediatric patients, including infants and neonates with suspected bacterial infections[7].
  • Treatment of infections in diabetic patients[8].

Potential Side Effects

Like all medications, dalbavancin can cause side effects. Common side effects may include:

  • Nausea
  • Headache
  • Diarrhea

More serious side effects are rare but can occur. It’s important to discuss potential risks and benefits with your healthcare provider[3].

Aspect Details
Drug Name Dalbavancin (also known as Xydalba or Dalvance)
Drug Class Lipoglycopeptide antibiotic
Administration Intravenous infusion
Key Indications Acute bacterial skin and skin structure infections (ABSSSI), osteoarticular infections, peritonitis, other Gram-positive bacterial infections
Dosing Regimens Single dose (1500 mg) or multiple doses (e.g., 1000 mg followed by 500 mg a week later)
Potential Benefits Long-acting nature, reduced hospital stays, improved patient convenience, potential cost savings
Ongoing Research Efficacy in various infections, use in special populations (e.g., infants, diabetics), hospital avoidance strategies
Safety Profile Generally well-tolerated, but further research needed in diverse patient populations

FAQ

  • What is dalbavancin? Dalbavancin is a long-acting antibiotic used to treat certain bacterial infections, particularly those caused by Gram-positive bacteria. It belongs to a class of drugs called lipoglycopeptides and is administered intravenously.
  • What types of infections can dalbavancin treat? Clinical trials are studying dalbavancin for treating acute bacterial skin and skin structure infections (ABSSSI), osteoarticular infections associated with hip and knee replacements, peritonitis in dialysis patients, and other Gram-positive bacterial infections.
  • How is dalbavancin administered? Dalbavancin is given as an intravenous infusion. Depending on the study and condition being treated, it may be given as a single dose or multiple doses spaced out over several weeks.
  • What are the potential benefits of dalbavancin compared to other antibiotics? Dalbavancin's long-acting nature allows for less frequent dosing, which may reduce hospital stays, improve patient convenience, and potentially lower healthcare costs. Some studies are exploring if it can help avoid hospital admissions altogether for certain infections.
  • Are there any safety concerns with dalbavancin? Like all medications, dalbavancin can have side effects. Clinical trials are closely monitoring for adverse events. So far, it appears to be generally well-tolerated, but more research is needed to fully establish its safety profile in different patient populations.

Ongoing Clinical Trials on Dalbavancin

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Continuous vs. Intermittent Infusion of Ampicillin and Ceftriaxone for Patients with Enterococcus faecalis Infective Endocarditis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria

  • Study on Dalbavancin and Rifampicin for Treating Prosthetic Joint Infections in Patients with Hip, Knee, and Shoulder Replacements

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Acute bacterial skin and skin structure infections (ABSSSI): A type of bacterial infection affecting the skin and underlying tissues, which can include cellulitis, wound infections, and abscesses.
  • Gram-positive bacteria: A class of bacteria that retain a certain stain (called Gram stain) due to their cell wall structure. Many common infectious bacteria are Gram-positive, including Staphylococcus and Streptococcus species.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Lipoglycopeptide: A class of antibiotics that includes dalbavancin, which work by interfering with bacterial cell wall synthesis.
  • Osteoarticular infections: Infections affecting bones and joints, which can be particularly serious when associated with prosthetic joints like hip and knee replacements.
  • Peritonitis: Inflammation of the peritoneum, the tissue lining the inner wall of the abdomen and covering the abdominal organs. In dialysis patients, it can be a serious complication of peritoneal dialysis.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Clinical response: The measurement of how well a patient's symptoms improve after receiving treatment.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT03696901
  2. https://clinicaltrials.gov/study/NCT02127970
  3. https://clinicaltrials.gov/study/NCT03372941
  4. https://clinicaltrials.gov/study/NCT04847921
  5. https://clinicaltrials.eu/trial/study-on-dalbavancin-and-rifampicin-for-treating-prosthetic-joint-infections-in-patients-with-hip-knee-and-shoulder-replacements/
  6. https://clinicaltrials.gov/study/NCT04624451
  7. https://clinicaltrials.gov/study/NCT02688790
  8. https://clinicaltrials.gov/study/NCT04959799